Join the RSV Vaccination and Immunization group to help and get support from people like you.
RSV Vaccination and Immunization News (Page 3)
Related terms: Respiratory Syncytial Virus Prophylaxis, RSV Prevention and Immunization
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK--(BUSINESS WIRE) October 22, 2024 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the...
Real-World Study Confirms RSV Vaccine's, Arexvy and Abrysvo, Protective Power for Seniors
FRIDAY, Oct. 18, 2024 – A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or...
IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
FRIDAY, Oct. 18, 2024 – Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an increasing social...
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
WEDNESDAY, Oct. 16, 2024 – Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows. About 1 in 4 people (26%) are now...
More Than Half of Infants Protected by Maternal RSV Vaccine, Nirsevimab, or Both
FRIDAY, Sept. 27, 2024 – In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research...
Ziresovir Reduces Signs, Symptoms of Bronchiolitis in Babies With RSV
FRIDAY, Sept. 27, 2024 – For infants and young children hospitalized with respiratory syncytial virus (RSV) infection, ziresovir reduces signs and symptoms of bronchiolitis, according to a study...
RSV Vaccination Effective Against Hospitalization in Patients 60 Years and Older
THURSDAY, Sept. 5, 2024 – For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the Journal of...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
FDA Approves Expanded Age Indication for GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
Philadelphia, PA June 07 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for...
FDA Approves mRESVIA (respiratory syncytial virus vaccine) for Prevention of Lower Respiratory Tract Disease Caused by RSV
CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory...